Bundibugyo Virus (BDBV) Research Reagents — Antibodies & Recombinant Proteins

Envelope Glycoprotein (GP) — Neutralization & Vaccine Target
GP is the sole surface protein mediating viral entry via NPC1 in endosomes. BDBV GP shares ~65% amino acid identity with ZEBOV GP — sufficient for partial cross-reactivity of some broadly neutralizing antibodies but too divergent for reliable protection by ZEBOV-specific therapeutics. Available:
• Pan-ebolavirus cross-reactive antibodies: BDBV223 (VK057013) — neutralizes BDBV, ZEBOV, and SUDV; and CA45 (VK057023) — broadly neutralizing antibody targeting a conserved GP epitope across multiple ebolavirus species
• Recombinant GP proteins: C-Fc (VK057011), N-His (VK057012), and C-His (VK057021) — three tag formats for ELISA coating, SPR binding, and immunogen evaluation
• Anti-GP polyclonal antibody (VK057014)

Nucleoprotein (NP) — Diagnostic Antigen
NP is the most abundant viral protein in infected cells and the primary target for filovirus diagnostic assays. BDBV NP can be used to develop BDBV-specific diagnostics and to assess cross-reactivity of pan-ebolavirus NP assays. Available: recombinant NP protein N-His (VK059012), anti-NP recombinant antibody SAA2994 (VK059013), and anti-NP polyclonal antibody (VK059014).

VP40 (Matrix Protein)
VP40 drives virion budding and determines the characteristic filamentous morphology of ebolaviruses. VP40 is also the basis for virus-like particle (VLP) production systems. Available: recombinant VP40 protein N-His (VK058012) and anti-VP40 polyclonal antibody (VK058014).

VP30 & VP24 — Transcription & Immune Evasion
VP30 is a zinc-binding transcription activator unique to filoviruses. VP24 inhibits IFN signaling by blocking STAT1 nuclear import. Both are drug target candidates. Available:
• VP30: recombinant protein N-His (VK060012) and anti-VP30 pAb (VK060014)
• VP24: recombinant protein N-His (VK061012) and anti-VP24 pAb (VK061014)

Do Inmazeb (ZEBOV-specific) antibodies work against BDBV?
Inmazeb (atoltivimab + maftivimab + odesivimab) was developed against ZEBOV GP and has limited cross-neutralization of BDBV due to ~35% GP sequence divergence. This is precisely why BDBV-specific and pan-ebolavirus reagents are needed. Our broadly neutralizing antibodies BDBV223 and CA45 neutralize BDBV, ZEBOV, and SUDV — critical tools for developing pan-ebolavirus therapeutics.

What is the difference between this page and the Ebola (EBOV) page?
Our Ebola page (catid=132) covers Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Reston ebolavirus (REBOV), and Taï Forest ebolavirus (TAFV), with biosimilar-grade reference antibodies (Inmazeb components, ZMapp, Ebanga). This BDBV page provides Bundibugyo-specific reagents. Cross-reactive antibodies (BDBV223, CA45) appear on both pages.

Can I work with these reagents at BSL-2?
Yes. All BDBV products are recombinant proteins and antibodies — no live or inactivated virus. Standard BSL-1/BSL-2 conditions are sufficient. Live BDBV requires BSL-4.

Explore reagents for related filoviruses:

Ebola (ZEBOV/SEBOV/REBOV) Bundibugyo (BDBV) ✓ Marburg (MARV)